Relation of HER2 Positive Breast Cancer Median Survival with CD44 Marker Expression

Abstract

The aim of this study was to investigation of the association between median survival of HER2-positive breast cancers with CD44 marker expression. Methods and materials: In this cross-sectional study, patients with HER2-positive breast cancer were examined for CD44 marker expression. Immunohistochemical method was used to evaluate CD44 status. Then, the patient’s survivals were determined by month, and for all patients, an overall survival (OS) was determined, and if possible, disease free survival (DFS) also evaluated. Further records including estrogen and progesterone receptor status, P53 and Ki67 were also recorded. Results: A total of 100 HER2-positive patients with mean age of 46.94 (±9.63) years were enrolled. The progesterone receptor was positive in 65% (65 patients) of patients and 71% (71 patients) had positive estrogen receptors. Ki67 receptor was positive in 73% (73 patients) and P53 was positive in 51% (51 patients). CD44 receptor was positive in 76% (76 patients) of patients and was negative in 24% (24 patients). In CD44-positive patients, the median OS rate was 69.27 (±3.62) months and the DFS rate was 69.52 (±3.9) months. There was no significant relationship between CD44 with OS and DFS, but based on cox regression results, there was a significant correlation between tumor size and OS and DFS. Also, estrogen receptor status had a significant correlation with OS and had no significant correlation with DFS.